Tenaya Therapeutics’ (TNYA) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research note released on Tuesday,Benzinga reports. They currently have a $18.00 price target on the stock.

Several other equities analysts have also commented on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and set a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a research report on Wednesday, December 18th. Finally, Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $17.33.

Tenaya Therapeutics Stock Down 5.4 %

TNYA stock opened at $1.39 on Tuesday. The stock has a market capitalization of $110.12 million, a price-to-earnings ratio of -0.97 and a beta of 2.89. The stock’s fifty day simple moving average is $2.26 and its 200-day simple moving average is $2.45. Tenaya Therapeutics has a 52-week low of $0.99 and a 52-week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.07. As a group, analysts anticipate that Tenaya Therapeutics will post -1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. abrdn plc purchased a new stake in Tenaya Therapeutics during the 3rd quarter worth $1,063,000. Jacobs Levy Equity Management Inc. grew its stake in shares of Tenaya Therapeutics by 204.4% during the third quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after acquiring an additional 226,466 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Tenaya Therapeutics by 144.1% during the second quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock worth $488,000 after acquiring an additional 92,960 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Tenaya Therapeutics by 35.6% in the third quarter. Wellington Management Group LLP now owns 294,133 shares of the company’s stock worth $568,000 after acquiring an additional 77,235 shares in the last quarter. Finally, Integral Health Asset Management LLC boosted its holdings in Tenaya Therapeutics by 3.3% in the second quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock valued at $7,208,000 after purchasing an additional 75,000 shares during the last quarter. 90.54% of the stock is currently owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.